Erleada 60mg, belongs to the classification of nonsteroidal antiandrogen (NSAA) medication which is needed in the therapy of prostate
cancer. It is especiallyrequired for use in conjunction with castration in the therapy of non-metastatic castration-resistant prostate cancer (NM-CRPC)
Erleada 60mg used as prescription medicine under the guidance of medical practioners. Erleada is safe or persuasive in children is unknown.
Erleada 60mg is prescribed for the therapy in patients with nonmetastatic castration-resistant prostate cancer (NM-CRPC)
MECHANISM OF ACTION
Apalutamide consist of nonsteroidal androgen receptor inhibitor; Apalutamide links directly to the androgen receptor ligand-binding domain to inhibits androgen-receptor translocation, DNA binding, and receptor-mediated transcription Androgen receptor prevention occurs in reduced multiplication of tumor cells and increased apoptosis, resulted to a decrease in tumor volume.
Duration to peak plasma concentration is 2hr and peak plasma concentration is 6mcg/mL and 5.9mcg/mL and steady-state achieved is 4 weeks
The drug Erleada has plasma protein bound of Apalutamide is 96% and N-desmethyl Apalutamide
Mainly the drug metabolized by CYP2C8 for the formation of N-desmethyl Apalutamide
Apalutamide eliminated via urine 65% and feces 24%
Half-life is 3 days
Erleada prescribed dose for adult is 240mg administrated four tablets contains 60mg given orally once daily.
The whole tablet should be swallow.
Erleada tablet can be taken with or without food.
Analogue with Apalutamide the patients should also getting a gonadotropin-releasing hormone (GnRH) along with concurrently or should have had a bilateral orchiectomy.
When patients suffered from ≥ grade 3 toxicity or impossible side effect then dosage modification should have needed.
While on treatment with Erleada 60mg tablets will causes falls and fractures, patients should evaluate for risk and monitor and manage patients at risk for fractures along with established treatment guidelines.
While on treatment Erleada 60mg may causes seizures then permanently discontinue if seizure occurs during treatment. Discuss with patients about growing risk due to seizure, it may cause sudden loss of memory while engaging in activities.
Erleada has caused some side effect but most people will not affect all the side effect listed
The drugs Common side effects which occurring in greater than 30% are;
Weakness , Low blood counts level, Cholesterol and triglyceridesIncreased, Blood sugar levelIncreased, Potassium levelsIncreased.
Less common side effects occurring in 10-29% :
Hot flashes, Skin rash, Vertigo/falling, Thyroid dysfunction , Muscle weakness, Joint pain, Decreased appetite, Hypertension, Diarrhea, Nausea, Peripheral edema , Falls, Fractures, Weight loss.
Erleada co administration with strong CYP2C8 or CYP3A4 inhibitor is determined to have high the steady state exposure of the active molecule.
Erleada co administration with mainly metabolized by CYP3A4, CYP2C19 or CYP2C9 can resulted in decrease exposure to these medications.
Erleada is contraindicated in pregnant women due to risk to fetal and possible loss of pregnancy
The drug is not used for females
Erleada will resultfetal harm and possible loss of pregnancy
Erleada is not indicated for female patients
Store the drug at 20°C to 25°C
Store in the original container
Protect from light and moisture.
If dose is forgot to take, then have the dose immediately before reach of next dose time or skip the missed dose and follow the normal schedule.
Consult the doctor about missed dose and overdose